Rising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...

There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...

Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...

Global financial markets are experiencing a risk-off shift driven by rising sovereign bond yields, impacting equities and commodities. Mark...

Indian markets ended lower on Tuesday as Sensex and Nifty erased early gains amid rupee weakness, even as volatility cooled. IT stocks outp...

Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...

Over a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...

The Bombay High Court has ruled in favour of Sun Pharmaceutical Industries. The court has restrained United Biotech from using a similar tr...

Market expert Amit Khurana offers insights on key corporate and regulatory developments. Sun Pharma's acquisition is seen as strategically ...

US company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...

Indian markets faced pressure extending a corrective phase. Key companies like RIL, IDFC First Bank, and Paytm reported their financial res...

Foreign institutional investors have been consistently selling shares in 146 Indian companies for four consecutive quarters. This selling s...

Sun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the India...

The Bombay High Court has ruled against a Navi Mumbai drugmaker. The court prohibited the use of brand names 'Absun' and 'Absun Pharma'. Th...

The US has slapped up to 100% tariffs on patented drugs, sparing generics and biosimilars but exposing India’s speciality pharma players. S...

Indian drug maker Sun Pharma faces significant exposure to potential US tariffs on medicines. Global brokerage Jefferies warns that while g...

The move could be a booster for Sun Pharma shares as corporate governance issues have weighed investor sentiment for the past two years.